posted on 2021-09-13, 23:43authored byDebra J. Wallace, Thomas Storz, Anna Balanov, William S. Kissel
Soluble guanylate cyclase (sGC) stimulators are small molecules that
increase nitric oxide (NO) signaling by binding to sGC, leading to
an increase in cyclic guanosine monophosphate production. Such compounds
have previously been studied clinically for noncentral nervous system
(CNS) disorders. CY6463 is the first CNS-penetrant sGC stimulator
to enter clinical trials and has the potential to positively impact
a range of neurodegenerative diseases. In this paper, we present the
development of an efficient, robust, and scalable synthesis of this
compound that allowed for rapid generation of larger quantities of
material, thereby accelerating advancement into early clinical studies,
while minimizing the use of resources. The synthesis features a palladium-catalyzed
one-pot Negishi coupling/cyanation sequence and a novel triazole formation
from a Boc-protected amidrazone. Optimization of the reactions, safety
considerations, and control of impurities, as well as a mechanistic
study of the triazole formation reaction, are discussed.